Incyte Drops Plans for Phase 3 MAESTRA-3 Ovarian Cancer Trial

John Kim

1 min read

Add as a preferred source on Google

Incyte Drops Plans for Phase 3 MAESTRA-3 Ovarian Cancer Trial

The study was designed to test INCB123667 with bevacizumab as first-line maintenance therapy for ovarian cancer.

By John Kim

Published Nov 13, 2026, 5:17 PM EST

Two sealed glass vials rest in a quiet clinical laboratory. / TokenPost.ai

Incyte has decided not to move ahead with its planned Phase 3 MAESTRA-3 trial, which was designed to test a drug combination as first-line maintenance therapy for ovarian cancer.

The study would have evaluated INCB123667 with bevacizumab.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.